BioCentury
ARTICLE | Clinical News

Eucreas vildagliptin/metformin regulatory update

March 3, 2008 8:00 AM UTC

The EC approved an MAA from Novartis for Eucreas vildagliptin/metformin to treat Type II diabetes. Eucreas is a single-tablet combination of vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, ...